Hematopoietic progenitors mobilization market: Is there time to change?

Abstract

The purpose of this review is to perform a comprehensive comparative analysis of different hematopoietic progenitor’s mobilizers with short excursus to mobilizers’ market development. Special attention is paid to the new drugs with great clinical perspectives.

Keywords

mobilization / HSC / oncohematology / regeneration therapy

References

[1] Appelbaum F.R. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. Cancer J. Clin. 1996; 46: 142-64.

[2] To L.B., Haylock D.N., Simmons P.J., Juttner C.A. The biology and clinical uses of blood stem cells. Blood 1997; 89(7): 2233-58.

[3] Kessinger A., McMannis J. Practical consideration of apheresis in peripheral blood stem cell transplantation. 1st ed. Lakewood: COBE Inc; 1994.

[4] Hoglund M. Glycosylated and non-glycosylated rhG-CSF - what is the difference? Med. Oncol. 1998; 15: 229-33.

[5] Martin-Christin F. Granulocyte colony-stimulating factors: how different are they? How to make a decision? Anti-Cancer Drugs 2001 ; 12: 185-91.

[6] Morris E.S., MacDonald K.P.A., Rowe V. et al. Donor treatment with pegylated G-CSF augments the generation of IL-10 producing regulatory T cells and promotes transplant tolerance. Blood 2004; 103: 3573-81.

[7] Nowrousian M.R., Waschke S., Bojko P. et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann. Oncol. (Suppl) 2003; 14: i29-36.

[8] http://www.clinicaltrials.gov/ct/show/NCT00208949?order=31

[9] Facon T., Harousseau J.L., Maloisel F. et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized clinical trial. Blood 1999; 94(4): 1218-25.

[10] Liles W.C., Broxmeyer H., Rodger E. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102(8): 2728-30.

[11] Urbano-Ispizua A. Risk assessment in hematopoietic stem cells transplantation: stem cell source. Best Pract. Res. Clin. Haematol. 2007; 20(2): 265-80.

[12] www.cancer.gov

[13] DiPersio J.F., Shuster M.W., Abboud C.N. et al. Mobilization of PBSC by concurrent administration of daniplestim and G-CSF in patients with breast cancer and lymphoma. J. Clin. Oncol. 2000; 18: 2762-71.

[14] Bishop M.R., Jackson J.D., O'Kane-Murphy B. et al. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. J. Clin. Oncol. 1996; 14: 2521-6.

[15] Morris E.S., MacDonald K.P., Rowe V. et al. Stem cell mobilization with novel G-CSF analogues augment NKT cell restricted graft-versus-leukemia effects. Biol. Blood Marrow Transpl. 2005: 11 (2; Sup.1): 45 (abstract 133).

[16] Carlo-Stella C., Di Nicola M., Milani R. et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287-95.

[17] Ballen K., Shpall E.J., Avigan D. et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol. Blood Marrow Transpl. 2007; 13(7): 838-43.

[18] Zohlnhofer D., Ott I., Mehilli J. et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295(9):1003-10.

[19] http://www.stemcellsummit.com/book-tour/index.html

[20] http://www.genzyme.com/corp/media/GENZ%20PR-080207.asp

[21] http://www.genzyme.com/corp/investors/GENZ%20PR- 071907.asp

[22] Copelan E.A. Hematopoietic stem cell transplantation. NEJM 2006; 354: 1813-26.

[23] www.clinicaltrials.gov

RIGHTS & PERMISSIONS

Eco-Vector